🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Elanco Animal Health Incorporated (ELAN)
NYSE: ELAN · Real-Time Price · USD
25.74
-0.55 (-2.09%)
At close: Nov 20, 2026, 4:00 PM EST
25.22
-0.52 (-2.04%)
After-hours: Nov 20, 2026, 7:30 PM EST
← View all transcripts

UBS Global Healthcare Conference

Nov 9, 2026

Summary

Q3 organic growth was 9%, with 4% pricing and 300 bps of gross-margin expansion. The 2027 outlook remains mid-single-digit revenue growth, supported by innovation, volume and continued efficiency gains.

Andrea Alfonso
Analyst, UBS

Good afternoon, everybody. I am Andrea Alfonso. I am with the healthcare services team here at UBS, and it is my pleasure to introduce you to Bobby Modi, EVP of U.S. Pet Health, and Bob VanHimbergen, who is the Chief Financial Officer of Elanco. To kick things off, maybe Bob, you would like to give some introductory remarks recapping last week's earnings calls and maybe all the new and exciting things going on at Elanco right now.

Bob VanHimbergen
CFO, Elanco

Yeah, great. Hey, thanks for having me, and thanks for the time today. Last Thursday, we did have our third quarter earnings release, and I think the message coming out of it is that momentum for the business continues from what we have seen the previous several quarters. Growth in the quarter was 9% organically, 11% reported, which included about a point of growth from AHV that we acquired here earlier this year. Pricing was a key topic going into the quarter, and pricing, we were pleased with the acceleration that we expected. Pricing in the quarter was 4%, a little bit higher on the pet side and a little bit lower than that on the farm side, but strong growth there. Overall, the business performed extremely well across all four quadrants. Our pet business grew 14%.

Bobby's U.S. Pet Health grew 13%, internationally grew 17%, really on the backs of continued share gains of some of our newer products. Earnings came in strong as well. Our gross margin was up 300 basis points from the previous year, really led from our innovation or our innovative products, a continued focus on our manufacturing capabilities, and really just continuous improvement processes throughout that, and then some favorable mix as we did grow stronger in the pet side. Earnings came in stronger than we expected, and then on the cash side and balance sheet, we did get levered below 3x . That was a key milestone for us.

We had originally expected that to be in 2027, and just with the stronger growth in earnings as well as continued fundamentals around trade working capital, we were able to get leverage at 2.9x . That was a major milestone for the company.

Andrea Alfonso
Analyst, UBS

Great. I guess last week, one thing that you did not really talk about as much was the reaffirmation of mid-single-digit organic revenue growth and high single-digit EBITDA growth for 2027. Maybe as we think about 2027, how much of the earnings algorithm is supported by volume, and then sort of share gains versus pricing mix, and then I have sort of an EBITDA follow-up to that.

Bob VanHimbergen
CFO, Elanco

Yeah, great. We highlighted last week, we have a tremendous amount of clarity around our 2027 business plan, and we will be meeting with the board next week to present that. Just a high degree of confidence, what we did do is reiterate our algorithm that we shared at Investor Day in December last year, which we did say we expect to grow mid-single digits from 2025 to 2028. We expect EBITDA to grow at high single digits, and we expect earnings to grow at low double digits. What we reiterated was, that is not only over the course of three years, but that is individually each year.

We did highlight, we expect that coming in 2027, and that is going to be a mix of both pricing. We do see pricing about that 2%-3% at the historical rate that we have been at. We expect that in Q4 and that to carry on into 2027. We see volume picking up the rest with some great growth in our innovation and the products around that.

Andrea Alfonso
Analyst, UBS

Got it. Just on the top line, one thing that we have certainly gotten questions on is the headwinds that you flagged from the Costco non-renewal. Is there a way for you guys to frame how big of a risk that is, and is that sort of limited to just one quarter?

Bob VanHimbergen
CFO, Elanco

Yeah, maybe I'll give you a couple comments and then I'll let Bobby give a little bit more color. But as you think about just the impact of Costco, what's important for people to understand is we actually see retail growing in 2027 versus 2026, even after considering the loss of the Costco business. Costco for the year, it was less than 0.5 point of growth for us. It was particularly stronger in Q1 in 2026 just because of the launch of it. But Bobby and the team have done a great job of adding more customers, and retail should be a growth driver for us next year.

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah, and it's not uncommon for us to see retailers make decisions on assortment, and Costco's a limited assortment environment. They carry only one SKU of flea and tick, and we had won that business from the incumbent for the first time in history, and they decided to make a different decision sort of going forward. This has happened to us before. We've lost major customers in the past, and we think it was largely driven by timing of execution and missing some part of the season when we sort of got in. And so, we're optimistic that the business will come back over time.

Andrea Alfonso
Analyst, UBS

And just to clarify, there's still a portion of your products that still is sold at Costco?

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah, I want to be very clear. That's a great follow-up question, Andrea. It's just our OTC business sold in the brick-and-mortar stores in Costco. W e still have our online OTC business, and we have a very large RX business with Costco as well.

Andrea Alfonso
Analyst, UBS

Okay. When you think about, you mentioned that these things do happen all the time. I guess, maybe just a flavor for how long these contracts typically run and what sort of drives them back to you guys at the end of the day?

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah. Typically, the contracts are on an annual cycle, and it is largely driven by performance. So, performance of something else that they put in there, whether that be another flea and tick product or, frankly, a different category altogether, and it is all about meeting certain velocity hurdles for dollars per store per club.

Andrea Alfonso
Analyst, UBS

Bob, just to touch on the EBITDA expansion that you are looking at. So, as you mentioned, gross margin improved 300 bps in Q3, and you also reiterated the 60% long-term target. How should investors think about the next leg of capture for 2027? You outlined quite a number of tangible drivers for Elanco Ascend. So maybe, has the low-hanging fruit kind of been plucked, if you will, for procurement, manufacturing, and operational efficiency? If we could just maybe go through some of the buckets of that would be helpful.

Bob VanHimbergen
CFO, Elanco

No, that is great. Yeah. So overall, with Elanco Ascend, we are still in the early stages of the benefit. We did see, obviously, we took a restructuring charge in December, and so what has been front-end loaded is just the G&A cost takeout. What you have seen is, in the last two quarters, we have talked about the acceleration of some of the programs and the projects under Elanco Ascend, and we have got over 5,000 projects that we are tracking. This is truly a global initiative where many hands are focused on improving what we do better today than we did a week ago, a month ago, and a year ago. We are just breaking down just some of those components. We do expect about 25% of the value of Elanco Ascend to be in G&A and 75% in margins.

The overall program, we expect to get $200 million-$250 million in EBITDA save by 2030. As I think about just the G&A, it's going to be leveraging AI, but a lot of it is just process improvements. The restructuring charge certainly gets us on the right footing moving forward. As I think about just the impacts to gross margin, it's going to be some pricing and some improvements in programs around gross to net, and understanding which projects and programs are more effective than others. Within the four walls of manufacturing facilities globally, just a continued effort on Kaizen events and ensuring that we're bringing best practices to what we do and sharing best practices across facilities around the world.

On the procurement side, I've highlighted even last December at Investor Day, I highlighted where the procurement team has negotiated new contracts. What we've seen, even this week, on our earnings call, we highlighted that we've had our first-ever supplier day. We had our top 70 strategic suppliers come to the office. I sat in many of these meetings myself. We're just a different spot in Elanco than we were two years ago and three years ago. We clearly see momentum sustaining, and we see an opportunity for partners to maybe partner a little bit differently and grow together. Our intent is to offset inflation as much as possible. There was a great receptivity from our supply base.

I think they recognize the trajectory we're on, both organically and the flexibility we have inorganically. I think you'll continue to see, over the next several years, a continued improvement in gross margins, a continued improvement in EBITDA margins as well. We kind of talk about the algorithm we gave at Investor Day. If I think about the formula that we use internally, Q3 was a great example of that, where on the G&A front in the quarter, we were up 2% year over year. If you back out higher incentive compensation costs because of the performance that we're having, we're actually down 2% year over year. That efficiency around Elanco Ascend has been funding the growth.

You saw us move up marketing and selling costs 18% in the quarter as we continued to grow that top line. You also saw us increase R&D expense 11% as we're focused on accelerating that pipeline, moving those products through that pipeline and investing more in strengthening that muscle. That's the internal formula we want to keep having, where we beat on our commitments, and then we continue to reinvest in the business. Elanco Ascend is at the core of that.

Andrea Alfonso
Analyst, UBS

Got it. Just switching gears to Befrena, which you mentioned would be the largest individual growth driver in U.S. Pet Health in 2027. I guess maybe, Bobby, if you could just sort of share how the Zenrelia launch experience, why or why should it not be like sort of the analog for how we think about Befrena from sort of a commercialization vis-a-vis your pricing strategy?

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah. I think, first of all, the IL-31 mAb category is roughly a $450 million market in the U.S., and there is only one player in there today. We think being number two with a differentiated asset on convenience, efficacy, and value is a huge competitive advantage. Maybe different than Zenrelia, which was slowed a little bit in the U.S. from a ramp perspective, driven by the label. Not only will we have a differentiated asset, but we also have sort of a clean label. Very similar to Zenrelia and all of our innovation, we price the value, right?

We also have attractive launch pricing that allows us to drive faster adoption and penetration in the marketplace. On a list price basis, we are roughly parity to the current market incumbent, but with a differentiated asset. We think that is going to be beneficial for us for driving penetration in the market at an accelerated rate once we fully release supply.

Andrea Alfonso
Analyst, UBS

Got it. Just maybe if you can sort of share, in terms of kind of the real-world usage, what is the longevity, if you will, of your competitor at this point?

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah, our competitor has a label efficacy of four to eight weeks. Our efficacy is on the six to eight week side. We believe they are operating historically more on the shorter end, and we hope that we will be operating at least the anecdotal information that we are getting from the market right now on the clinics that have adopted thus far, we are getting on sort of the longer side of use. There will be real value opportunity for either the pet parent or the vet clinic going forward.

Andrea Alfonso
Analyst, UBS

Got it. With a third injectable potentially coming into the market, just sort of as you think about the TAM, is the TAM really, is sort of the ceiling really just sort of the third of the market that is not seasonal, sort of more chronic? Could it be more than that? Then I had a follow-up question.

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah, I think whenever you can drive value and convenience, you should be able to grow the market. Our expectation and what we see historically with innovation is that the market ultimately grows, and I think compliance ultimately drives dosage use, which ultimately creates growth in the TAM.

Andrea Alfonso
Analyst, UBS

What do you see the U.S. derm and OUS derm market for these products growing at the moment? Because I think we have also heard that derm visits are down, as are many of sort of the chronic/therapeutic visits.

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah. OUS, we certainly see the derm market growing high single digits, I think, on a revenue basis. In the U.S., what we continue to see is, based on the data that we have, that doses are up, but you're seeing a little bit shift in one product to another that may be trading dollars out of the category. You're seeing dollars maybe more flat to slightly down in the U.S. derm market, but doses up.

Andrea Alfonso
Analyst, UBS

O bviously with the third market coming in, third player rather, coming in with longer efficacy, if you will. I guess, you've spoken to a lot of derm specialists, and I think also sort of your experience having been in this space for a while. I mean, I remember that at one point, when we certainly had Jeff on the road in March, that there was some hesitation on pet owners as well in terms of just kind of having a product that long in the pet's body. Do you think that that would kind of be the same for derm, where there's sort of this natural feeling of like, "Well, I only want X number of this in my pet's body before I start to worry"?

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah, I think there's a couple ways to think about it. First is roughly 2/3 of the pet patients are either acute or seasonal, which means they're using the product for less than three months, right? So there's really not a need for a long-acting product. Befrena's sort of perfect for that. The second thing is really about sort of real-world market performance, right? So if Befrena's performing even better than maybe what the labeled efficacy is, or consumers are able to stretch it, that also sort of gives us the ability to carry over to some longer-acting doses. And the third thing we know from recent experiences, there's a subset of veterinarians and pet parents that have hesitancy about sort of long-lasting injectables, and largely just concerns about safety, which also sort of creates an opportunity for a product like Befrena.

Andrea Alfonso
Analyst, UBS

This is a bit of a two-parter, which is also linked to Befrena. But, Bob, marketing spend was up in the teens, 9% organic growth. You are going to be doing a pretty major launch, and I know that there are nuances there, but how do we sort of think about that pace versus organic growth? Does it narrow a little bit in 2027? And I guess just to circle back to Befrena, how do you think that the makeup of the spend could trend? Could it be similar to your prior derm?

Bob VanHimbergen
CFO, Elanco

Yes. Let me, I'll speak at the macro level. As I think about moving forward, think about 2027, we absolutely expect to see more leverage coming through the P&L on the spend. With that being said, we're going to continue to lean in and use data. All of our decisions around DTC are data-driven. You've seen it in the share gains that we've had, not only in the U.S., but also internationally. We're going to continue to use data. Elanco Ascend plays heavy into this, but we use data to determine how much and the effectiveness of the DTC spend. We continue to see that return on those investments. Until we see that peak out, we're going to continue to lean in there. At least in 2027, we do see some leverage coming through the P&L.

Bobby Modi
EVP of U.S. Pet Health, Elanco

The way I think about the business is the two largest components of our spend are our media, direct-to-consumer advertising, and then our sales force sort of expenditure on our share of voice. On the media side, what I would tell you is there are categories that are more vet-driven and categories that are more consumer-driven. Categories that are more consumer-driven, think parasiticide. On those categories, there's a significant amount of media or direct-to-consumer investment. Categories that are more vet-driven, so think dermatology or other therapeutic categories, there's actually not that much direct-to-consumer advertising.

Actually, we're spending very little on Zenrelia. We expect to spend very little on Befrena going forward. On the flip side, share of voice is your voice with the customer. As our portfolio grows and we continue to sort of extend our reach with more products, we are actually increasing in our share of voice by actually adding sales reps in the marketplace to cover the vast growing portfolio that we have in the U.S.

Andrea Alfonso
Analyst, UBS

Oh, that's helpful. Just switching gears to sort of the topic du jour.

Bobby Modi
EVP of U.S. Pet Health, Elanco

Pricing?

Andrea Alfonso
Analyst, UBS

Pricing. Exactly. Topic du jour.

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah.

Andrea Alfonso
Analyst, UBS

Topic of the year. I guess, just obviously on pricing, Jeff talked about time-based activity in the quarter. Maybe if you could comment on sort of You've also mentioned it's rational. Maybe like what's different this time around? We're a little bit early in, I guess, in Q4, but maybe if you can also comment on whether that's intensified or sort of been stable in Q4.

Bob VanHimbergen
CFO, Elanco

Yeah. Maybe I'll start off, and then Bobby can talk more about what he's seeing now. Think about pricing, so think about where we landed in Q3. Really, we expected acceleration in price, and we saw that. Couple drivers to pricing, right? It's always going to be a matter of customer mix and product mix, timing of corporate accounts, and those sort of things lapping. But we had a high degree of confidence and clarity around that, and we saw that. What we're seeing pricing, because the strength we're seeing is because of the basket of innovation growing. So think about a Zenrelia and a Quattro product. Last year, didn't have pricing. Now it does because we're lapping initial launches of those programs. We do see fluctuations quarter to quarter.

We're anticipating that coming back to the 2%-3% in Q4, and that's the, as we think about 2027, we've committed to that mid-single digit growth. I would consider that 2%-3% of pricing and the rest being really volumes. Overall pricing, we're going to continue to price to the value that we bring to the end customer, and we think that's very high. We've been clear, we haven't, nor do we expect to engage in a severe pricing dynamic, and we haven't needed to, and we don't anticipate doing that. All those things are sort of short-term duration things that could shift purchases and sales by a month here or there. But ultimately, best medicine's going to win, and that's been really the philosophy that we've been on, and we've seen that success. But maybe Bobby can add a little bit more color.

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah, I would just say that we think pricing in the market has been really responsible. At any given time, you will see what I would call a competitor make time-bound or surgical investments at an account largely driven by gross-to-net investments. Actually, what we are seeing is Q4 really is not that different than Q3. In some ways, Q4 has moderated a little bit from where Q3 was from a pricing perspective. I would just reiterate, it has been responsible for many years. It continues to be responsible, and we expect that to continue going forward.

Andrea Alfonso
Analyst, UBS

Got it. In cases like that, do you react? Is it even matched from what you have seen so far, or do you just walk away from that volume?

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah, I think when it is surgical and time-bound, the way I would think about it is, you think about our drivers of growth, it is continuing to add new clinics to our innovation. The pace of adding new clinics was consistent with what we have always communicated, roughly 500 a month on Quattro and 500 a month on Zenrelia. We do not see clinics switch back from our products because we believe we have sort of best medicine out there. All it does is potentially move volume from one quarter to another quarter into a clinic that maybe delays our ability to convert that clinic. Eventually, we will come to them when their stock is low and hopefully convince them that we have got the best offering for their customers going forward.

Andrea Alfonso
Analyst, UBS

Got it. Just zooming in a little bit on some of your older products. I guess, U.S. Pet Health grew 13% in Q3. It was driven by Zenrelia and Quattro. Where do you see the greatest remaining opportunity? Is it still new clinics? Is it deeper utilization in the existing clinics, or is it maybe sales outside the traditional vet channel?

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah, I think about our growth in three ways. There is the growth of our existing big six innovation. The growth of those products is going to be driven by new clinics. Credelio Quattro is in roughly 55% of the clinics, so there is still ample opportunity to grow. Zenrelia is in 2/3 of the clinics, so still ample opportunity to add more clinics. Second is getting increasing share in those clinics, and what you naturally see is when you onboard a clinic later in the year, your share is lower in the clinic than what it will be if you get them during sort of peak season. Third is we participate in growing segments. We expect our products to grow as a result of those segments. Then the fourth is the price sort of benefit that we get.

The other factor that will drive our business is obviously new innovation, like Befrena. We think there is a significant portfolio benefit of Befrena. 20% of clinics that brought in Befrena had never brought in Zenrelia, and so that is an ample hunting ground for our clinics going forward. Then the third area is the effect of innovation on your base portfolio. What we saw this year is 2,600 clinics that brought in Quattro bought another Elanco product for the first time ever, adding several millions of dollars of sales this year.

Andrea Alfonso
Analyst, UBS

When you are sort of thinking about the number or rather the maximum number of products, you know, in a shelf, does it sort of vary across the board? How does para compare to derm?

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah, we generally see clinics carry fewer parasiticide products in clinic going forward. One, they are watching inventory. Two, they are watching sort of cash. They can utilize their home delivery platform for other para products if a consumer desires it. On derm, because the disease state is tricky and complicated to treat, and usually there are multiple solutions needed depending on what the derm needs are of the dog, we actually see clinics carrying multiple JAK inhibitors and other treatments like cyclosporine or monoclonal antibodies to treat the product. So, I really think it depends on the therapeutic category and what the vet needs to sort of deliver care to the pet.

Andrea Alfonso
Analyst, UBS

Got it. I guess just on Quattro, it was really interesting in September, we saw a press release talking about the extended tick and flea season. I guess just drilling on that, just as you think about the ability to, if a competitor were to intensify their efforts to take away share, how do we think about the opportunity during non-peak season, which is kind of where we are, and how effective can that strategy ultimately be? Then just on this topic of an extended season, is this a structural change or is this one that might possibly present a tough comp at the same time next year?

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah. I mean, look, the drivers of flea and tick, just from a weather perspective, tend to be moisture and warmer weather. As we see warmer weather, generally speaking, and we're seeing a little bit more moisture right now, the season is extending. Now, it may not be extending in the vet clinic, because what we know is there's a slightly different shopping behavior for consumers, specifically as it relates to preventatives. It's more of an omnichannel behavior where they're buying more online, whether it be the vet's online pharmacy or in the retail channel, which again, is a win for the industry because it drives compliance up.

Generally speaking, it is difficult to bring clinics on in an off-season time period because they're unwilling to go through the change management with pet parents now, because then they've got to reeducate a whole slew of new consumers during the peak season. You generally see share gains slow down during this off-peak cycle, and then it'll really pick back up in call it the Feb, March timeframe when the season really picks up through the late summer.

Andrea Alfonso
Analyst, UBS

Got it. So if you think about just the ability to convert, you have fairly compliant pet owners, hopefully, and who are on it. It should just be like the one-year point, or the pet just doesn't really like the taste and wants to go to chewable or some sort.

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah. I think the way to think about it is we think about new starts, which is why we care about Puppy Index, which Puppy Index is a leading indicator of we're converting more puppies than our fair share, which means our share should ultimately catch up over time. Then, you look for a triggering event. There are two ways that you can get a triggering event. There is obviously the pet parent comes in and says, "My dog won't eat this," or, "My dog doesn't like this." There is also converting a clinic. You can drive change management in a clinic and have the clinic sort of communicate the benefits of moving to Quattro, for example, because of the more comprehensive coverage that it offers versus other medicines in the marketplace.

Andrea Alfonso
Analyst, UBS

Got it. Bob, just obviously wanted to kind of pivot back to sort of some more finance questions. I think with all sort of the dynamics that were going on in the quarter, I think what was maybe not asked as much was about the strides you have made in terms of cleaning up the balance sheet. So, as you mentioned, net leverage now below 3x . There was a line in there in the slides that said you have greater capital flexibility. What does that mean?

Bob VanHimbergen
CFO, Elanco

Yeah. So great, and thanks for the question. Yeah, it really did not get any airtime on the call. First off, the global team has done a fantastic job of focusing on the fundamentals around trade working capital and cash, and so you continue to see those fundamentals improve. As I think about what that means for us, our capital allocation strategy has not changed. Our first priority is going to continue to be paying down debt and investing in the business organically, and so that is going to continue to be investing in R&D capabilities and manufacturing capacity. M&A is going to be a part of our growth strategy as well, but I would say the size of those are generally going to be smaller tuck-under opportunities, really extending a pipeline or adding to the portfolio.

Nothing that is going to be significant enough where it would move us away from our deleveraging target, where we expect to get to that 2x- 2.5x is kind of the end goal there. If you go back to December of 2025 at Investor Day, I highlighted that when we get below 3x , that unlocks the opportunity for shareholder return. We thought that was going to be in 2027. We have accelerated where we are in those expectations. So, where we are today, as you can imagine, we are ahead of schedule there, and so we are having conversations with our board on that, and looking forward to making sure that investors are aware of that status, and we will be transparent on those discussions.

I really like the space of where we are, where we have accelerated that by a good amount of time.

Andrea Alfonso
Analyst, UBS

On the potential for strategic M&A, does that kind of figure into the calculus? What assets would be interesting or even additive to the business?

Bob VanHimbergen
CFO, Elanco

Yeah. So great question. The way we think about M&A, if I think about my role, it has got to be accretive to the algorithm. It has got to have a great financial return. When I think about that, I always start with ROIC. Is it going to have an ROIC that is well above our weighted average cost of capital? It has got to be accretive to the algorithm. So is it going to grow mid-single digits? Is profitability going to grow high single digits? Is it going to support an LDD EPS? It cannot skew us away from our deleveraging target of getting to that 2.5x .

Think of the spaces. It is going to be really the spaces that we are in today. It is going to be in the derm portfolio. It is going to be in parasiticides. It is going to be in farm animal. AHV was a fantastic acquisition that we did earlier this year, really growing our ruminant strategy that we have. A couple months in, that acquisition has been fantastic. Integration has gone very well. We are growing at or even a little bit above what the business case had. The other thing that AHV brought for us, by the way, is it has added, it has doubled our share of voice with the farm business. We have got an extra set of, or doubled the size of our share of voice.

We did not put into our business case any opportunity from cross-selling, but that certainly exists. That is going to be sort of the profile, Andrea. It is going to be something that is not going to be [rails] from a cash perspective, but got some good upside.

Andrea Alfonso
Analyst, UBS

Speaking of other things that did not get attention in this conversation, but farm, obviously, is, I mean, is it still realistic to think that this is a low single-digit market? Where do you think that you could continue to grow above the market, and what really drives that as you were thinking about maturing assets, like Experior, for example?

Bob VanHimbergen
CFO, Elanco

Yeah. So, great. Yeah. So, we think it is a low single-digit to mid-single-digit industry, and we see a long runway over the next decade. Really, three drivers as we think about what that would be. The first one is just the U.S. dietary guidelines recommending more protein in diets. Number two would be the aging population, where by 2030, we do expect the aging population over 60 to grow by 25%, and then the need for protein in that population is higher. Then the use of GLP-1s. We predict that by 2035, 20% of Americans will be on a GLP-1. That population today eats 30%-40% more protein than those that are not on that. So, those macro drivers, I think, continue to support that farm business.

Our portfolio, we have got some differentiated assets with Experior and Rumensin, and opportunity to globalize Experior over the next several years, get pricing as well. We feel great about the industry. We feel great about our portfolio in that. So, I see us growing at or above the market.

Andrea Alfonso
Analyst, UBS

Great. Bobby, I just wanted to touch a little bit on innovation. Obviously, back at Analyst Day, you outlined quite a number of assets in the pipeline. I guess a lot of focus has been on CKD in a lot of ways because you do have a competitor that has an active asset there. Maybe could you talk about from a high level, like what is structurally different? I think we have all heard that there are certain challenges there. Do you think solutions range from just the need for diagnosis because it is not absent? Is it having to bring felines where it is more prevalent? So, just sort of love your view there.

Bobby Modi
EVP of U.S. Pet Health, Elanco

Yeah. Here is what I would say. At Investor Day, we outlined our innovation assets, and we committed to five to six products by 2031, out of 15 projects. Fast-forward 11 months, we have had zero attrition from the pipeline. The R&D team, led by Ellen, is doing a phenomenal job. Yes, while we have assets in feline CKD, and we think it is a robust space, what I am more excited about is that we have assets in pain, derm, parasiticides that have the potential to be first in class and best in class.

What I would tell you, having done this a couple times, is it is a lot easier to enter existing large growing markets with differentiated assets than try to go create a new market with a new asset. We will do both, but I have a lot more confidence in sort of going in the established spaces and what that will bring going forward.

Andrea Alfonso
Analyst, UBS

Bobby, I am a little disappointed you did not bring up obesity, which is my favorite.

Bobby Modi
EVP of U.S. Pet Health, Elanco

We also have obesity. We do have obesity, which is also a very exciting space to be.

Andrea Alfonso
Analyst, UBS

Great. Well, listen, with just the remaining time, maybe high level what, as you think about kind of the risks to that outlook for 2027, what do you think the biggest risk is to achieving it? Then conversely, what do you think has to happen to outperform it?

Bob VanHimbergen
CFO, Elanco

Yeah. We had that question earlier today, and it's a great question, right? Page 21 of our deck highlighted the initial thoughts on headwinds and tailwinds. With that balance, we firmly believe and have a high degree of confidence and clarity around what 2027 looks like. That's why we were able to speak with such conviction on our 2027 initial guide, if you will, being in line with the algorithm. No, to me, I think Befrena launching and ramping up is probably the highest nail, if you will, but not something that we're overly concerned with.

Bobby and I talked earlier today with a group of investors, and even like Costco, right? There's a great example where they got a lot of questions. We had a lot of questions on Costco, but it was less than 0.5 point of our growth, and we grew through it. I think we've got enough levers that we can absolutely hit the commitments that we gave.

Andrea Alfonso
Analyst, UBS

Wonderful. Well, thank you so much to you both for your support here in UBS and making the trip, and to Tiffany Kanaga, Head of IR in the audience as well. Yeah, we'll wrap up here.

Bob VanHimbergen
CFO, Elanco

Yeah. Thank you.

Bobby Modi
EVP of U.S. Pet Health, Elanco

Thanks for having us.

Andrea Alfonso
Analyst, UBS

Thank you so much.

Bobby Modi
EVP of U.S. Pet Health, Elanco

Appreciate it.